INMUNOTEK has participated in the commercial exhibition of the annual EAACI congress held in Prague (Czech Republic) on 1-3 July. Although it has also been held in hybrid form and hampered by the mobility restrictions that still exist in many countries, it has had a large number of attendees.

INMUNOTEK featured in CIO Bulletin’s “50 Most Admired Companies to Watch 2022” list after being nominated for its business performance based on innovative and competitive products in the allergy and immunology fields.

Sello IeE

INMUNOTEK obtains the CIEGE Seal for excellence in business management for the third consecutive year granted by Informa-ElEconomista. This Seal certifies excellent management over 57 indicators from 10 categories: solvency, profitability, growth, employment, internationalization, corporate social responsibility, customer satisfaction, innovation, commercial risk management and digitization.

INMUNOTEK has once again been awarded the CEPYME500 seal in its 2021 edition, which recognizes the 500 leading Spanish companies in business growth, both for their results and their ability to generate added value, employment, innovation and international projection. This is the third year that INMUNOTEK has received this distinguished seal.

INMUNOTEK and IDIPAZ (Research Institute of the Hospital Universitario La Paz) have signed an agreement to deepen the mechanisms of action of a new anticancer vaccine developed by INMUNOTEK within the RETOS-Collaboration program with the participation of the Hospital Clínico San Carlos, Universidad Complutense de Madrid and CIB-CSIC.

INMUNOTEK has been present at the annual EAACI congress (European Academy of Allergy and Clinical Immunology) held on July 10-12, for the first time in hybrid form between Krakow and Madrid.

INMUNOTEK has participated in the XLV Congress of the SEICAP (Spanish Society of Clinical Immunology, Allergology and Pediatric Asthma) in the session “Meeting with the Expert” entitled “Mite allergens and their cross-reactivity. From scientific evidence to real practice in pediatric patients”.

Comunidad Madrid

The Department of Science, Universities and Innovation of the Community of Madrid, has held a meeting with INMUNOTEK to evaluate the industrial doctorate program. This program is an initiative of the executive of the Community of Madrid to promote public-private collaboration through the completion of doctoral theses in an academic and business environment.

cepyme500 2020

INMUNOTEK listed in CEPYME500, 2020 edition. This is an initiative of CEPYME (State Confederation of Small and Medium Enterprises) to identify, recognize and support the 500 leading companies in business growth in Spain. INMUNOTEK was already listed in 2017.

EPO

The European Patent Office has granted to INMUNOTEK the patent EP2982381B1. This refers to hypoallergenic neoglycoconjugates performed with non-oxidized mannan derived from S. cerevisiae to be used for the development of novel allergy vaccines targeting dendritic cells.